source
- AI bio startup Boltz secures $110 million Series A as AI drug design platform usage surgesBoltz, an artificial‑intelligence driven biotech startup, announced a $110 million Series A financing round less than a year after emerging from stealth with an initial $28 million investment. The…
- FDA rejects Summit Therapeutics' PD-1/VEGF bispecific ivonescimab after Phase 3 failureThe U.S. Food and Drug Administration declined to grant approval for ivonescimab, a bispecific antibody that targets PD‑1 and VEGF and was being developed by Summit Therapeutics in collaboration wi…